Trial
NCT02013167
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Intervention
Blinatumomab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-05